Delivery Method: UPS NEXT DAY DELIVERY Reference #: 2016-DAL-WL-26 Product: Drugs Recipient:

Recipient Name

Marshall A. Dunlap

Best Bentonite Best Bentonite

11650 Otis Rd
Guthrie, OK 73044
United States

Issuing Office:

United States

Marshall A. Dunlap – Owner
Best Bentonite
11650 Otis Rd
Guthrie, OK 73044

Mr. Dunlap:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 2016-DAL-WL-26 dated June 17, 2016. Based on our evaluation during, it appears that you have addressed the violations contained in this Warning Letter related to your marketing of Best Bentonite. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
LCDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

  • Content current as of:

    11/30/2018

Source